Chiesi Global Rare Diseases and Protalix BioTherapeutics announced that the European Commission has approved an additional dosing regimen for pegunigalsidase alfa, marketed as Elfabrio, allowing certain adults with Fabry disease who are stable on enzyme replacement therapy to receive infusions every four weeks instead of every two weeks. The authorization follows a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use and is supported by data from the BRIGHT clinical study evaluating safety, efficacy, and pharmacokinetics of the extended dosing schedule.

The decision does not introduce a new therapy for Fabry disease, but it directly addresses one of the most persistent challenges associated with enzyme replacement therapy: treatment burden. For patients living with a lifelong lysosomal storage disorder that requires intravenous infusions for decades, the cadence of therapy becomes a defining feature of disease management. Reducing infusion frequency therefore represents more than a logistical change. It reflects a growing industry focus on improving how therapies fit into patients’ daily lives.

How reducing infusion frequency could reshape the long-term treatment burden in Fabry disease management

Fabry disease results from mutations in the GLA gene that impair the activity of the enzyme alpha galactosidase A, leading to progressive accumulation of globotriaosylceramide in tissues. Over time, this accumulation damages organs including the kidneys, heart, and nervous system. Without treatment, the disease can lead to kidney failure, cardiomyopathy, and increased risk of stroke.

Because the metabolic defect persists throughout life, enzyme replacement therapy must be administered continuously. For most therapies used in Fabry disease, the standard dosing interval has historically been every two weeks, a schedule that has remained largely unchanged since the early era of enzyme therapy development.

The practical consequences of this schedule are significant. Each infusion typically requires several hours and often involves travel to specialized infusion centers or coordination of home infusion services. Patients may also require monitoring for infusion reactions.

Over years or decades of treatment, the cumulative burden becomes substantial. A patient treated for twenty years under a biweekly schedule may undergo more than five hundred infusion visits. Reducing dosing frequency to once every four weeks effectively halves the number of annual infusions, potentially easing the logistical and psychological burden associated with lifelong therapy.

What the BRIGHT study indicates about pharmacokinetic stability with extended dosing intervals

The regulatory approval was informed primarily by results from the BRIGHT clinical study, an open label switch trial evaluating pegunigalsidase alfa administered at a dose of 2 mg per kilogram every four weeks. Participants were adults with Fabry disease who were already stable on enzyme replacement therapy before switching to the extended dosing interval.

Switch studies are commonly used to evaluate dosing changes for existing therapies. Rather than demonstrating superiority, these trials aim to confirm that modified dosing schedules maintain therapeutic exposure and safety profiles comparable to the standard regimen.

In the BRIGHT study, investigators assessed pharmacokinetic parameters, adverse events, and biochemical markers associated with Fabry disease over a fifty two week treatment period. The results suggested that monthly dosing maintained pharmacokinetic exposure consistent with effective enzyme replacement while demonstrating a safety profile comparable to previous clinical experience.

Clinicians tracking lysosomal storage disorders often emphasize that pharmacokinetics is particularly important when extending dosing intervals for enzyme therapies. Because these drugs deliver functional enzyme to compensate for a metabolic deficiency, maintaining sufficient activity between infusions is critical to preventing substrate accumulation.

Although the trial provides reassurance regarding short term stability, it does not fully address long term outcomes such as renal decline or cardiac disease progression. These clinical endpoints typically require several years of observation.

How dosing flexibility could reposition Elfabrio within the evolving Fabry disease treatment landscape

The Fabry disease treatment landscape has historically been dominated by enzyme replacement therapies administered through intravenous infusion. Therapies such as agalsidase beta and agalsidase alfa established the biweekly dosing paradigm that remains standard in many treatment centers.

Pegunigalsidase alfa represents a newer entrant developed by Protalix BioTherapeutics using a plant cell expression platform and commercialized in Europe by Chiesi Global Rare Diseases. The therapy was designed to provide sustained enzyme exposure and potentially improved pharmacokinetic characteristics.

The addition of a once monthly dosing option may give the therapy a distinct positioning advantage in a market where treatment convenience increasingly influences prescribing decisions. When clinical efficacy between therapies appears broadly comparable, physicians and patients often prioritize factors such as infusion frequency and overall treatment burden.

However, the new dosing schedule is restricted to adults who are already stable on enzyme replacement therapy. This limitation means the regimen will likely be used selectively rather than replacing standard dosing for newly diagnosed patients or those with unstable disease.

Which clinical uncertainties regulators and physicians may continue to monitor after approval

Despite the potential advantages of reduced infusion frequency, clinicians often approach dosing modifications cautiously in progressive metabolic diseases. Fabry disease progression can be gradual and subtle, meaning that the effects of insufficient metabolic control may not become visible for several years.

Regulatory observers therefore expect ongoing monitoring of clinical outcomes as the extended dosing regimen enters routine clinical practice. Biomarkers associated with substrate accumulation, kidney function measurements, and cardiac imaging findings will likely remain central indicators used to assess disease stability.

Another question involves immunogenicity. Enzyme replacement therapies can trigger antibody responses that influence treatment effectiveness or infusion reactions. Whether altering infusion frequency changes immune response dynamics remains uncertain and may require longer term observational data.

Real world evidence will therefore be essential in confirming whether the monthly regimen maintains disease control across diverse patient populations. Patient registries and post approval studies are expected to play a significant role in tracking these outcomes.

Why treatment convenience is becoming a central innovation theme across rare disease therapies

The European Commission decision reflects a broader shift in rare disease drug development toward reducing treatment burden alongside improving clinical efficacy. Earlier generations of therapies focused primarily on restoring missing biological functions. As treatment standards mature, attention has increasingly turned to optimizing treatment delivery.

Several approaches are currently being explored across the rare disease sector. These include long acting enzyme formulations, subcutaneous administration strategies, and gene therapies designed to enable sustained endogenous enzyme production.

Within this broader context, extending dosing intervals represents a pragmatic step that can improve patient experience without requiring entirely new therapeutic technologies. Even incremental reductions in treatment burden can be meaningful for patients who expect to remain on therapy for decades.

Healthcare system considerations also play a role. Fewer infusion visits may reduce pressure on specialized treatment centers and lower administrative costs associated with repeated intravenous therapy.

Why the EU dosing approval triggers a meaningful regulatory milestone payment for Protalix BioTherapeutics

The approval of the extended dosing regimen also carries financial implications for Protalix BioTherapeutics. Under the partnership agreement between the Israeli biotechnology company and Chiesi Global Rare Diseases, the authorization triggers a milestone payment of 25 million dollars.

Milestone payments are common within biotechnology licensing agreements and provide non dilutive funding tied to regulatory progress or commercial performance. Such payments can strengthen a company’s financial position while supporting continued research and development activities.

For Protalix BioTherapeutics, the milestone underscores the continued regulatory lifecycle expansion of pegunigalsidase alfa within the Fabry disease market. Lifecycle strategies such as dosing flexibility can extend the relevance of therapies even as new modalities, including gene therapies, move through development.

Clinicians and industry observers will now watch how rapidly the monthly dosing option is adopted across European healthcare systems. If real world data confirm that reduced infusion frequency maintains disease stability, the approach could represent a meaningful step toward reducing the lifelong treatment burden associated with Fabry disease management.

  BRIGHT trial, Chiesi Global Rare Diseases, Elfabrio, enzyme replacement therapy, Fabry disease, pegunigalsidase alfa, Protalix BioTherapeutics, rare diseases